PHARMA MAR - 1H - Technical analysis published on 02/22/2024 (GMT)
- 136
- 0
Click here for a new analysis!
- Timeframe : 1H
- - Analysis generated on
- Status : TARGET REACHED
Summary of the analysis
Additional analysis
Quotes
The PHARMA MAR rating is 33.08 EUR. The price registered a decrease of -0.24% on the session and was traded between 32.86 EUR and 33.72 EUR over the period. The price is currently at +0.67% from its lowest and -1.90% from its highest.The Central Gaps scanner detects a bullish opening marking the presence of buyers ahead of sellers at the opening but not sufficiently marked to allow the price to register a quotation gap.
Bullish opening
Type : Bullish
Timeframe : Openning
Here is a more detailed summary of the historical variations registered by PHARMA MAR:
Near a new LOW record (1st january)
Type : Bearish
Timeframe : Weekly
Near a new LOW record (1 month)
Type : Bearish
Timeframe : Weekly
Technical
Technical analysis of PHARMA MAR in 1H shows a overall strongly bearish trend. 92.86% of the signals given by moving averages are bearish. The overall trend is supported by the strong bearish signals from short-term moving averages. There is no crossing of moving average by the price or crossing of moving averages between themselves.
The technical indicators are generally neutral. They do not provide relevant information on the direction of future price movements.
Caution: the Central Indicators scanner currently detects an excess:
Williams %R indicator is oversold : under -80
Type : Neutral
Timeframe : 1 hour
Pivot points : price is under support 1
Type : Neutral
Timeframe : Weekly
Central Patterns, the market scanner focusing on chart patterns, resistances and supports found these results:
Near horizontal resistance
Type : Bearish
Timeframe : 1 hour
Near resistance of channel
Type : Bearish
Timeframe : 1 hour
No result was found by the Central Candlesticks scanner on Japanese candlesticks.
S3 | S2 | S1 | Price | R1 | R2 | R3 | |
---|---|---|---|---|---|---|---|
ProTrendLines | 28.21 | 30.00 | 31.39 | 33.08 | 33.43 | 36.12 | 38.02 |
Change (%) | -14.72% | -9.31% | -5.11% | - | +1.06% | +9.19% | +14.93% |
Change | -4.87 | -3.08 | -1.69 | - | +0.35 | +3.04 | +4.94 |
Level | Major | Intermediate | Minor | - | Intermediate | Intermediate | Major |
To determine price objectives, it is also possible to use the pivot points. Here is the price position in relation to pivot points:
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 32.01 | 32.41 | 32.79 | 33.19 | 33.57 | 33.97 | 34.35 |
Camarilla | 32.95 | 33.02 | 33.09 | 33.16 | 33.23 | 33.30 | 33.38 |
Woodie | 31.99 | 32.41 | 32.77 | 33.19 | 33.55 | 33.97 | 34.33 |
Fibonacci | 32.41 | 32.71 | 32.90 | 33.19 | 33.49 | 33.68 | 33.97 |
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 31.06 | 32.54 | 33.30 | 34.78 | 35.54 | 37.02 | 37.78 |
Camarilla | 33.44 | 33.65 | 33.86 | 34.06 | 34.27 | 34.47 | 34.68 |
Woodie | 30.70 | 32.36 | 32.94 | 34.60 | 35.18 | 36.84 | 37.42 |
Fibonacci | 32.54 | 33.40 | 33.92 | 34.78 | 35.64 | 36.16 | 37.02 |
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 31.77 | 34.79 | 36.77 | 39.79 | 41.77 | 44.79 | 46.77 |
Camarilla | 37.39 | 37.84 | 38.30 | 38.76 | 39.22 | 39.68 | 40.14 |
Woodie | 31.26 | 34.53 | 36.26 | 39.53 | 41.26 | 44.53 | 46.26 |
Fibonacci | 34.79 | 36.70 | 37.88 | 39.79 | 41.70 | 42.88 | 44.79 |
Numerical data
The following is the status of technical indicators and moving averages registered at the time this technical analysis was created:
RSI (14): | 41.47 | |
MACD (12,26,9): | -0.2100 | |
Directional Movement: | -0.15 | |
AROON (14): | 28.57 | |
DEMA (21): | 32.90 | |
Parabolic SAR (0,02-0,02-0,2): | 32.86 | |
Elder Ray (13): | -0.09 | |
Super Trend (3,10): | 33.73 | |
Zig ZAG (10): | 33.02 | |
VORTEX (21): | 0.8900 | |
Stochastique (14,3,5): | 21.48 | |
TEMA (21): | 32.97 | |
Williams %R (14): | -77.78 | |
Chande Momentum Oscillator (20): | -0.10 | |
Repulse (5,40,3): | -0.2200 | |
ROCnROLL: | 2 | |
TRIX (15,9): | -0.1100 | |
Courbe Coppock: | 2.09 |
MA7: | 33.90 | |
MA20: | 36.29 | |
MA50: | 39.26 | |
MA100: | 37.08 | |
MAexp7: | 33.09 | |
MAexp20: | 33.21 | |
MAexp50: | 33.77 | |
MAexp100: | 34.72 | |
Price / MA7: | -2.42% | |
Price / MA20: | -8.85% | |
Price / MA50: | -15.74% | |
Price / MA100: | -10.79% | |
Price / MAexp7: | -0.03% | |
Price / MAexp20: | -0.39% | |
Price / MAexp50: | -2.04% | |
Price / MAexp100: | -4.72% |
News
Don't forget to follow the news on PHARMA MAR. At the time of publication of this analysis, the latest news was as follows:
- Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants
- PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
- PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan
- Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line
- PharmaMar Announces the U.S. FDA Approval of lurbinectedin (Zepzelca™) for the Treatment of Metastatic Small Cell Lung Cancer
Add a comment
Comments
0 comments on the analysis PHARMA MAR - 1H